HVB MINI FUTURE BULL - ASTRAZENECA | Delayed Deutsche Boerse AG 11:34:16 11/06/2024 BST | ||
| 5.86 EUR | -2.50% |
|
| Current month | +9.47% | ||
| 1 month | +6.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 11/06/24 | 5.86 | -2.50% |
| 10/06/24 | 6.01 | +1.52% |
| 07/06/24 | 5.92 | -0.50% |
| 06/06/24 | 5.95 | +1.02% |
| 05/06/24 | 5.89 | +2.43% |
Delayed Quote Deutsche Boerse AG
Last update June 11, 2024 at 11:34 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR6WGF |
| ISIN | DE000HR6WGF8 |
| Date issued | 16/04/2021 |
| Strike | 7,526 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.89 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.05 € |
|---|---|
| Lowest since issue | 0.8 € |
| Spread | 0.01 € |
| Spread % | 0.17% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
160.3
USD
Average target price
174.4
USD
Spread / Average Target
+8.77%
- Stock Market
- Certificates
- Certificat
